zenodorestricted
Cytopenias and failure to use innovative therapy are main drivers of worse outcome after discontinuation of ruxolitinib in chronic phase myelofibrosis
ShareScore
12/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 4
- Harmonization
- 0
- Access
- 8
- Reuse readiness
- 0
- Engagement
- 0
Dataset details
- Repository
- zenodo
- Published
- October 7, 2024
- License
- cc-by-4.0
- DOI
- 10.5281/zenodo.13902217
Scored with release 0.9.0
ScienceDex for faculty
Your academic CV and NIH biosketch
Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.